DIAGNOSTIC TEST PANEL 501

ANCA Vasculitis/Anti-GBM Disease (Goodpasture Syndrome)

Diagnostic test panel for antibodies against GBM, dsDNA, PR3, and MPO. For suspicion of ANCA-associated systemic vasculitis.

Indication

Diagnosis and follow-up of ANCA-associated systemic vasculitis (such as Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (GPA)).

Clinical background

Patients with GPA (formerly called Wegener’s granulomatosis) have, with few exceptions, ANCA. About 90% have PR3-ANCA, and 5-10% have MPO-ANCA. In patients with a limited disease and in patients in remission ANCA is positive in half the cases.

Patients with microscopic polyangiitis (MPA) are, as a rule, positive for MPO-ANCA, but cases with positive PR3-ANCA occur. Even patients with Churg-Strauss disease and Goodpasture syndrome may be positive for MPO-ANCA. Both in the case of GPA and of MPA an increase in the ANCA level may precede a relapse.

References

  • Arranz, O et al.Comparison of anti-PR3 capture and anti-PR3 direct ELISA for detection of ANCA in long-term clinical follow-up of PR3-ANCA-associated vasculitis patients. Clinical Nephrology 2001; 56: 295-301.
  • Csernok E, Ahlquist D, Ullrich S, Gross W.L. A critical evaluation of commercial immunoassays for antineutrophil cytoplasmic antibodies directed against proteinase 3 and myeloperoxidase in Wegener’s granulomatosis and microscopic polyangiitis. Rheumatology 2002;41:1313-1317.
  • Csernok E, Holle J, Hellmich B et al. Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener’s granulomatosis: first results from a multicenter study. Rheumatology 2004; 43: 174-180
  • Gisslen, K et al.Relationship between ANCA determined with conventional binding and the capture assay and long-term clinical course in vasculitis.J. Intern Med 2002; 251: 0129-135.
  • Sanders et al. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumatology 2006; 45: 724-729.
  • Savage COS et al. ABC of arterial and vascular disease - Vasculitis. Br Med J 2000; 320: 1326-1328
  • Savige, J et al. ANCA and associated diseases: A review of the clinical and laboratory features. Kidney Int 2000; 57: 846-862.
  • Segelmark M, et al. How and why should we detect ANCA? Clin Exp Rheumatol 2000, 18, 629-635.
  • Westman, K et al.Relaps rate, renal survival and cancer morbidity in patients with Wegener’s granulomatosis or microscopic polyangiitis with renal involvement.J Am Soc Nephrol 1998; 9: 842-852.
  • Won H, et al.Serial ANCA titers. Useful tool for the prevention of relapses in ANCA associated vasculitis. Kidney Int, 2003, 63, 1079-1085.

Tests included in panel

Need pricing information?

Get a quote

How to order

This test panel is available worldwide for hospitals, clinics, and physicians.

  1. Print and complete the request form

    Download the request form. Clearly state the name and phone number of the referring hospital, clinic, or physician.

  2. Prepare your samples

    Serum: At least 0.5 mL serum (plain serum tubes without additives).

  3. Send samples and request form

    Within Sweden
    Samples can be sent at room temperature to:
    Envelopes and smaller boxes:
    Wieslab AB, Box 50117, 20211 Malmö, Sweden

    Larger boxes and frozen samples:
    Wieslab AB, Lundavägen 151, 21224 Malmö, Sweden

    International
    Samples can be sent at room temperature to:
    Wieslab AB, Lundavägen 151, 21224 Malmö, Sweden

Read our sampling instructions for more information

Last updated: 2025-08-18